Division of Endocrinology and Metabolic Diseases, Department of Medicine and Surgery, University of Parma, AOU of Parma, Italy.
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome and Università Cattolica del Sacro Cuore, Rome, Italy.
Nutr Metab Cardiovasc Dis. 2019 May;29(5):496-503. doi: 10.1016/j.numecd.2019.01.011. Epub 2019 Feb 8.
Fostering patient's self-managing of basal insulin therapy could improve glucose control, by removing patient's and physician's barriers to basal insulin initiation, titration and glucose monitoring. The Italian Titration Approaches Study (ITAS) aims at demonstrating non-inferiority (<0.3% margin) in efficacy of glucose control (change in glycated hemoglobin [HbA1c] after 24 weeks) by the same titration algorithm of insulin glargine 300 U/mL (Gla-300), managed by the (nurse assisted) patient versus the physician, in insulin naïve patients with Type 2 Diabetes Mellitus (T2DM), uncontrolled with previous treatments.
ITAS is a phase IV, 24-week, national, multicenter, open label, randomized (1:1) parallel group study. 458 patients were enrolled, 359 randomized, and 339 completed the study, in 46 Italian centers. Baseline characteristics and previous medications of the ITT population (N = 355) are reported. Mean ± SD age, T2DM duration, HbA1c, FPG and BMI were 64.0 ± 9.8 years, 11.6 ± 7.6 years, 8.79 ± 0.65%, 170.9 ± 42.3 mg/dL, and 30.3 ± 5.6 kg/m, respectively. Vascular and metabolic disorders were most frequent (73.8% and 58.3%, respectively). More than 90% of patients were on metformin.
ITAS is the first study to compare two different managers (nurse-assisted patient vs physician) of the same titration algorithm of Gla-300 in insulin naïve patients with T2DM in unsatisfactory glucose control. This study might provide novel evidence on the efficacy/effectiveness of patient-managed titration algorithm of Gla-300 in a pragmatic setting and may reduce barriers to basal insulin initiation and its titration.
通过消除患者和医生在起始、调整剂量和血糖监测方面对基础胰岛素的使用障碍,促进患者自我管理基础胰岛素治疗,可能改善血糖控制。意大利调整剂量方法研究(ITAS)旨在证明在血糖控制方面(24 周后糖化血红蛋白[HbA1c]的变化)不劣于(差值<0.3%)使用甘精胰岛素 300U/mL(Gla-300)相同的调整剂量算法,由(护士辅助的)患者与医生共同管理,用于治疗之前治疗控制不佳的 2 型糖尿病(T2DM)的胰岛素初治患者。
ITAS 是一项为期 24 周的、全国性的、多中心的、开放性标签、随机(1:1)平行分组研究。共纳入 458 例患者,359 例患者随机分组,339 例患者完成研究,共涉及 46 家意大利中心。报告了 ITT 人群(N=355)的基线特征和之前的用药情况。355 例患者的平均(±标准差)年龄、T2DM 病程、HbA1c、FPG 和 BMI 分别为 64.0±9.8 岁、11.6±7.6 年、8.79±0.65%、170.9±42.3mg/dL 和 30.3±5.6kg/m2。血管和代谢疾病最常见(分别为 73.8%和 58.3%)。超过 90%的患者正在服用二甲双胍。
ITAS 是第一项比较两种不同管理者(护士辅助的患者与医生)在血糖控制不佳的 T2DM 胰岛素初治患者中使用相同的 Gla-300 调整剂量算法的研究。该研究可能为在真实环境中患者管理的 Gla-300 调整剂量算法的疗效/有效性提供新的证据,并可能降低基础胰岛素起始和调整剂量的障碍。